Data Set Name: seneca_final_data.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	SENECA_ID	Char	9	$9.	$9.	Newly generated ID
2	tx	Num	8	BEST.		Study treatment condition (0=placebo, 1=allo-MSCs)
3	main	Num	8	BEST.		Randomized vs Open Label (0= open label lead-in subject, 1= randomized participant)
4	Gender	Num	8	BEST.		Subject's gender (Male =1, Female=2)
5	Hispanic	Num	8	BEST.		Subject is of Hispanic ethnicity (self reported 1=yes, 2=no, 99=not reported)
6	Diabetes	Num	8	BEST.		Subject has a history of Diabetes (self reported, 1=yes, 2=no)
7	Hypertension	Num	8	BEST.		Subject has a history of Hypertension (self reported, 1=yes, 2=no)
8	Hyperlipidemia	Num	8	BEST.		Subject has a history of Hyperlipidemia (self reported, 1=yes, 2=no)
9	Hypercholesterolemia	Num	8	BEST.		Subject has a history of Hypercholesterolemia (self reported, 1=yes, 2=no, 99=not reported)
10	Hypertriglyceridemia	Num	8	BEST.		Subject has a history of Hypertriglyceridemia (self reported, 1=yes, 2=no, 99=not reported)
11	BMI	Num	8	15.2		Body Mass Index at baseline (kg/m^2)
12	Smoking	Num	8	BEST.		Subject has a history of smoking (self reported, 1=never, 2=previous, 3=current)
13	SmokingYears	Num	8	BEST.		Years smoked
14	SmokingPacksPerDay	Num	8	BEST.		Number of packs per day
15	AtrialFibrillation	Num	8	BEST.		Subject has a history of Atrial fibrillation (self reported, 1=yes, 2=no)
16	VentriArrhythm	Num	8	BEST.		Subject has a history of Ventricular arrhythmias (self reported, 1=yes, 2=no)
17	ValvularHeartDisease	Num	8	BEST.		Subject has a history of Valvular heart disease (self reported, 1=yes, 2=no)
18	PeriVascuDisease	Num	8	BEST.		Subject has a history of Peripheral vascular disease (self reported, 1=yes, 2=no)
19	Leukemia	Num	8	BEST.		Subject cancer history includes Leukemia (0=no, 1=yes)
20	BreastCancer	Num	8	BEST.		Subject cancer history includes Breast cancer (0=no, 1=yes)
21	Hodgkins	Num	8	BEST.		Subject cancer history includes Hodgkin's disease (0=no, 1=yes)
22	NonHodgkins	Num	8	BEST.		Subject cancer history includes Non-hodgkin's lymphoma (0=no, 1=yes)
23	Sarcomas	Num	8	BEST.		Subject cancer history includes Sarcomas (0=no, 1=yes)
24	OtherCancers	Num	8	BEST.		Subject cancer history includes other cancers not noted above (0=no, 1=yes)
25	MultipleCancers	Num	8	BEST.		Subject reported having more than one type of cancer during lifetime (0=no, 1=yes)
26	HeartRate	Num	8	BEST.		Subject's heart rate at baseline [beats per minute]
27	BloodPressureSBP	Num	8	BEST.		Subject's systolic blood pressure recorded at baseline [mmHg]
28	BloodPressureDBP	Num	8	BEST.		Subject's diastolic blood pressure recorded at baseline [mmHg]

Num	Variable	Type	Len	Format	Informat	Label
29	NYHAClass	Num	8	BEST.		Subject's New York Heart Association Classification at baseline (class 2=2, class 3=3)
30	Angina	Num	8	BEST.		Subject reported history of angina at baseline (1=yes, 2=no)
31	ICD	Num	8	BEST.		Subject has an implantable cardiac device (1=yes, 2=no)
32	SubjectICD	Num	8	BEST.		Type of ICD implanted (1=pacemaker only, 3=ICD, 5=Biventricular pacing and ICD)
33	CABG	Num	8	BEST.		Subject reported history at baseline of coronary bypass graft procedure (1=yes, 2=no)
34	PCI	Num	8	BEST.		Subject reported history at baselineof percutaneous coronary intervention (1=yes, 2=no)
35	HFHospitalization	Num	8	BEST.		Subject reported previous hospitalizations for heart failure at baseline (1=yes, 2=no)
36	HFEDVisits	Num	8	BEST.		Subject reported previous emergency department visits for heart failure at baseline (1=yes, 2=no)
37	Doxorubicin	Num	8	BEST.		Antineoplastic treatment included this anthracycline (0=no, 1=yes)
38	Epirubicin	Num	8	BEST.		Antineoplastic treatment included this anthracycline (0=no, 1=yes)
39	Daunorubicin	Num	8	BEST.		Antineoplastic treatment included this anthracycline (0=no, 1=yes)
40	Idarubicin	Num	8	BEST.		Antineoplastic treatment included this anthracycline (0=no, 1=yes)
41	Liposomal	Num	8	BEST.		Antineoplastic treatment included this anthracycline (0=no, 1=yes)
42	OtherAnthracyclines	Num	8	BEST.		Antineoplastic treatment included anthracycline not otherwise noted above (0=no, 1=yes)
43	Her2	Num	8	BEST.		Subject had treatment including this other potentially cardiotoxic agent (0=1, 1=yes)
44	Tyrosine	Num	8	BEST.		Subject had treatment including this other potentially cardiotoxic agent (0=1, 1=yes)
45	OtherCardiotoxic	Num	8	BEST.		Subject had treatment including another potentially cardiotoxic agent not otherwised noted above (0=1, 1=yes)
46	Cyclophosphamide	Num	8	BEST.		Subject had treatment that included this other chemotherapy (0=no, 1=yes)
47	Cytoxan	Num	8	BEST.		Subject had treatment that included this other chemotherapy (0=no, 1=yes)
48	Paclitaxel	Num	8	BEST.		Subject had treatment that included this other chemotherapy (0=no, 1=yes)
49	Taxotere	Num	8	BEST.		Subject had treatment that included this other chemotherapy (0=no, 1=yes)
50	OtherChemotherapy	Num	8	BEST.		Subject had treatment that included another chemotherapy not otherwise noted above (0=no, 1=yes)
51	NeverReceivedRadiation	Num	8	BEST.		Subject has never received radiation (0=no, 1=yes)
52	WholeBreast	Num	8	BEST.		Subject has received radiation to the whole breast (0=no, 1=yes)
53	PartialBreast	Num	8	BEST.		Subject has received radiation to part of the breast (0=no, 1=yes)
54	Mastectomy	Num	8	BEST.		Subject has received radiation to the post mastectomy chest wall (0=no, 1=yes)
55	Mammary	Num	8	BEST.		Subject has received radiation to the internal mammary field (0=no, 1=yes)
56	Axillary	Num	8	BEST.		Subject has received axillary radiation (0=no, 1=yes)

Num	Variable	Type	Len	Format	Informat	Label
57	Mantle	Num	8	BEST.		Subject has received radiation to the mantle field (0=no, 1=yes)
58	OtherRadiation	Num	8	BEST.		Subject has received radiation not otherwise noted above (0=no, 1=yes)
59	RadiationLeftChest	Num	8	BEST.		Subject has received radiation that included the left chest wall (0=no, 1=yes)
60	YearsSinceAIC	Num	8	BEST.		Years since AIC diagnosis
61	YearsSinceTreatment	Num	8	BEST.		Years since last treatment with an anthracycline
62	AICExposure	Num	8	BEST.		Anthracycline dose [cumulative in mg/m^2] (when available)
63	YearsSinceCancerDiag	Num	8	BEST.		Years since last cancer diagnosis
64	ACEAngioEntresto	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes) [ACE inhibitors/angiotensin II blockers/Entresto]
65	Aldosterone	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
66	Antiarrhythmics	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
67	Anticoagulation	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
68	Antidiabetics	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
69	Antiplatelets	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
70	Aspirin	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
71	BetaBlockers	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
72	CCBs	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes) [Calcium channel blockers]
73	Diurectics	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
74	Hydralazine	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
75	Insulin	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
76	Ivabradine	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
77	Nitrates	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
78	Statins	Num	8	BEST.		Subject taking medication in this drug class at baseline (0=no, 1=yes)
79	RecvdProd	Char	1	$1.	$1.	Subject received study product injections (0=no, 1=yes)
80	Total_Injections	Char	2	$2.	$2.	Total number of injections received (min=0, max=20)
81	Total_Volume	Char	3	$3.	$3.	Total fluid volume injected (min=0, max=8 ml)
82	_6MAttend	Char	1	$1.	$1.	Subject attended 6 Month follow up visit (0=no, 1=yes)
83	_12MAttend	Char	1	$1.	$1.	Subject attended 12 Month follow up visit (0=no, 1=yes)

Num	Variable	Type	Len	Format	Informat	Label
84	DAOH_All	Num	8	15.		Days alive and out of the hospital during the 395 day follow up evaluation period (hospitalization was >24hrs for any cause)
85	DAOH_HF	Num	8	15.		Days alive and out of the hospital during the 395 day follow up evaluation period (hospitalization was >24hrs for heart failure)
86	CE_death	Num	8	15.		Clinical endpoint of death criteria was met (0=no, 1=yes). Endpoint adjudication definitions supplied with BioLINCC submission.
87	CE_Hsplz_HF	Num	8	15.		Clinical endpoint of hospitalization for heart failure criteria was met (0=no, 1=yes). Endpoint adjudication definitions supplied with BioLINCC submission.
88	CE_HF_Exacer	Num	8	15.		Clinical endpoint of heart failure exacerbation (non-hospitalization) was met (0=no, 1=yes). Endpoint adjudication definitions supplied with BioLINCC submission.
89	CE_NFstroke	Num	8	15.		Clinical endpoint of non-fatal stroke criteria was met (0=no, 1=yes). Endpoint adjudication definitions supplied with BioLINCC submission.
90	CE_NFMI	Num	8	15.		Clinical endpoint of non-fatal myocardial infarction criteria was met (0=no, 1=yes). Endpoint adjudication definitions supplied with BioLINCC submission.
91	CE_CAR	Num	8	15.		Clinical endpoint of coronary artery revascularization criteria was met (0=no, 1=yes). Endpoint adjudication definitions supplied with BioLINCC submission.
92	CE_VT_VF	Num	8	15.		Clinical endpoint of ventricular tachycardia/fibrillation criteria was met (0=no, 1=yes). Endpoint adjudication definitions supplied with BioLINCC submission.
93	CE_PT	Num	8	15.		Clinical endpoint of pericardial tamponade criteria was met (0=no, 1=yes). Endpoint adjudication definitions supplied with BioLINCC submission.
94	CE_IM	Num	8	15.		Clinical endpoint of infectious myocarditis criteria was met (0=no, 1=yes). Endpoint adjudication definitions supplied with BioLINCC submission.
95	CE_HR	Num	8	15.		Clinical endpoint of hypersensitivity reaction criteria was met (0=no, 1=yes). Endpoint adjudication definitions supplied with BioLINCC submission.
96	CE_Neop	Num	8	15.		Clinical endpoint of neoplasm criteria was met (0=no, 1=yes). Endpoint adjudication definitions supplied with BioLINCC submission.
97	LVEF_b	Num	8	BEST.		Left ventricular ejection fraction (assessed via MRI) at baseline
98	LVEF_6	Char	5	$5.	$5.	Left ventricular ejection fraction (assessed via MRI) at 6 Months post injection
99	LVEF_12	Char	5	$5.	$5.	Left ventricular ejection fraction (assessed via MRI) at 12 Months post injection
100	HarpGlobalCircSt_b	Char	8	$8.	$8.	Global circumferential strain (assessed via MRI) at baseline
101	HarpGlobalCircSt_6	Char	8	$8.	$8.	Global circumferential strain (assessed via MRI) at 6 Months post injection
102	HarpGlobalCircSt_12	Char	8	$8.	$8.	Global circumferential strain (assessed via MRI) at 12 Months post injection
103	HarpGlobalLongSt_b	Char	8	$8.	$8.	Regional longitudinal strain (assessed via MRI) at baseline

Num	Variable	Type	Len	Format	Informat	Label
104	HarpGlobalLongSt_6	Char	8	$8.	$8.	Regional longitudinal strain (assessed via MRI) at 6 Months post injection
105	HarpGlobalLongSt_12	Char	8	$8.	$8.	Regional longitudinal strain (assessed via MRI) at 12 Months post injection
106	LVEDVI_b	Num	8	BEST.		Left ventricular end diastolic volume index (assessed via MRI) at baseline (note indices are volumes normed by body surface area)
107	LVEDVI_6	Char	7	$7.	$7.	Left ventricular end diastolic volume index (assessed via MRI) at 6 Months post injection
108	LVEDVI_12	Char	7	$7.	$7.	Left ventricular end diastolic volume index (assessed via MRI) at 12 Months post injection
109	LVESVI_b	Num	8	BEST.		Left ventricular end systolic volume index (assessed via MRI) at baseline (note indices are volumes normed by body surface area)
110	LVESVI_6	Char	7	$7.	$7.	Left ventricular end systolic volume index (assessed via MRI) at 6 Months post injection
111	LVESVI_12	Char	7	$7.	$7.	Left ventricular end systolic volume index (assessed via MRI) at 12 Months post injection
112	SphericityIndex_b	Num	8	BEST.		Left ventricular Sphericity Index (assessed via MRI) at baseline (note sphericity index is the ratio of the long and short axis measurements of the left ventricle)
113	SphericityIndex_6	Char	6	$6.	$6.	Left ventricular Sphericity Index (assessed via MRI) at 6 Months post injection
114	SphericityIndex_12	Char	6	$6.	$6.	Left ventricular Sphericity Index (assessed via MRI) at 12 Months post injection
115	ScarSizePer_b	Char	5	$5.	$5.	Scar size percent (percentage of mass assessed via MRI DEMRI) at baseline
116	ScarSizePer_6	Char	5	$5.	$5.	Scar size percent (percentage of mass assessed via MRI DEMRI) at 6 Months post injection
117	ScarSizePer_12	Char	5	$5.	$5.	Scar size percent (percentage of mass assessed via MRI DEMRI) at 12 Months post injection
118	ScarTissueMass_b	Char	5	$5.	$5.	Scar tissue mass ([in grams] assessed via MRI DEMRI) at baseline
119	ScarTissueMass_6	Char	5	$5.	$5.	Scar tissue mass ([in grams] assessed via MRI DEMRI) at 6 Months post injection
120	ScarTissueMass_12	Char	5	$5.	$5.	Scar tissue mass ([in grams] assessed via MRI DEMRI) at 12 Months post injection
121	ViableMass_b	Char	6	$6.	$6.	Viable tissue mass ([in grams] assessed via MRI DEMRI) at baseline
122	ViableMass_6	Char	6	$6.	$6.	Viable tissue mass ([in grams] assessed via MRI DEMRI) at 6 Months post injection
123	ViableMass_12	Char	6	$6.	$6.	Viable tissue mass ([in grams] assessed via MRI DEMRI) at 12 Months post injection
124	Viablemassperc_b	Char	6	$6.	$6.	Viable tissue mass percent (percentage of mass assessed via MRI DEMRI) at baseline
125	Viablemassperc_6	Char	6	$6.	$6.	Viable tissue mass percent (percentage of mass assessed via MRI DEMRI) at 6 Months post injection
126	Viablemassperc_12	Char	6	$6.	$6.	Viable tissue mass percent (percentage of mass assessed via MRI DEMRI) at 12 Months post injection

Num	Variable	Type	Len	Format	Informat	Label
127	asinsqrtViablemassperc_b	Char	7	$7.	$7.	Transformed value (using arc sine square root) of Viable tissue mass at baseline
128	asinsqrtViablemassperc_6	Char	7	$7.	$7.	Transformed value (using arc sine square root) of Viable tissue mass at 6 Months post injection
129	asinsqrtViablemassperc_12	Char	7	$7.	$7.	Transformed value (using arc sine square root) of Viable tissue mass at 12 Months post injection
130	DistanceWalked_b	Num	8	BEST.		Six Minute Walk Test Distance Walked (in meters) at baseline (two tests per visit [separated by 30 minutes]; the average of the two tests used for analysis)
131	DistanceWalked_6	Char	5	$5.	$5.	Six Minute Walk Test Distance Walked (in meters) at 6 Months post injection
132	DistanceWalked_12	Char	5	$5.	$5.	Six Minute Walk Test Distance Walked (in meters) at 12 Months post injection
133	SummaryScore_b	Num	8	BEST.		Minnesota Living with Heart Failure Questionnaire Summary Score at baseline (min score=0, max= 105; lower scores indicative of better outcomes)
134	SummaryScore_6	Char	4	$4.	$4.	Minnesota Living with Heart Failure Questionnaire Summary Score at 6 Months post injection
135	SummaryScore_12	Char	5	$5.	$5.	Minnesota Living with Heart Failure Questionnaire Summary Score at 12 Months post injection
136	PROBNP_b	Num	8	BEST.		NT-proBNP value at baseline
137	PROBNP_6	Char	5	$5.	$5.	NT-proBNP value at 6 Months post injection
138	PROBNP_12	Char	5	$5.	$5.	NT-proBNP value at 12 Months post injection
139	lPROBNP_b	Num	8	BEST.		Transformed value (using log transformation) of NT-proBNP value at baseline
140	lPROBNP_6	Char	7	$7.	$7.	Transformed value (using log transformation) of NT-proBNP value at 6 Months post injection
141	lPROBNP_12	Char	7	$7.	$7.	Transformed value (using log transformation) of NT-proBNP value at 12 Months post injection
142	RACE	Num	8			Redacted Race value: 1=White, 2=African American, 3=Other, 99=Not reported
143	AGE_NEW	Num	8			Age in years at the time of consent - redacted to integer value
144	LeukemiaDays	Num	8			Leukemia diagnosis - days since radomization
145	BreastCancerDays	Num	8			Breast Cancer - days since radomization
146	HodgkinsDays	Num	8			Hodgkins - days since radomization
147	NonHodgkinsDays	Num	8			Non Hodgkins - days since radomization
148	SarcomasDays	Num	8			Sarcomas - days since radomization
149	OtherCancersDays	Num	8			Other Cancers - days since radomization
150	RecentTmtDays	Num	8			completion of most recent anthracyline treatment - days since radomization
151	ImplantDays	Num	8			device implantation - days since radomization
152	AICDiagDays	Num	8			Anthracycline induced cardiomyopathy (AIC) diagnosis - days since radomization
153	Hsplz_Days3	Num	8			third heart failure hospitalization - days since radomization
154	ProdDays	Num	8			study product infection - days since radomization

Num	Variable	Type	Len	Format	Informat	Label
155	Death_Days	Num	8			death - only one of these - days since radomization
156	Hsplz_Days1	Num	8			first heart failure hospitalization - days since radomization
157	Hsplz_Days2	Num	8			second heart failure hospitalization - days since radomization
158	Exacer_Days	Num	8			heart failure exacerbation - only one of these - days since radomization
159	HR_Days	Num	8			hyersensitivity reaction - only one of these - days since radomization